Compare ACM Research Inc (ACMR) vs Inovio Pharmaceuticals Inc (INO) Price & Performance

ACMR trades at $81.26, up 2.33% today, with a neutral technical signal and bearish moving averages. The stock shows strong fundamentals with Q2 2026 EPS beating estimates at $0.61 versus $0.42 expected, revenue growth of 36% year-over-year to $292.9 million, and raised 2026 guidance. Net income margin improved to 14.48% in 2026 from 10.43% in 2025, supported by robust orders and product expansion.

Outlook remains positive with an 80% analyst buy rating and consensus price target of $127.50, implying significant upside. Risks include high P/E of 37.7, negative operating cash flow, and semiconductor cycle volatility. Growth catalysts are new wet processing platforms and overseas expansion, but execution on guidance is critical.

INO trades at $0.772, up 4.83% in the last 24 hours, but technical indicators signal a bearish trend. The company shows minimal revenue of $65,340 in 2025 with a net loss of $84.95 million, though it has beaten EPS estimates in recent quarters. Key developments include an upcoming Q2 2026 earnings report on August 12, 2026, and a pending FDA decision on INO-3107 by October 30, 2026.

The outlook hinges on FDA approval of INO-3107, with a consensus price target of $3.25 implying significant upside. However, high cash burn, negative margins, and legal scrutiny pose substantial risks. Investors should weigh the binary event against persistent financial challenges.